Our gastroenterology portfolio ranks among the top 10 in the Indian Pharmaceutical Market (IPM).
We at Lupin have established a strong presence in gastrointestinal and hepatic care through a comprehensive portfolio of therapies, strategic partnerships, and patient-centric initiatives.
Our gastroenterology portfolio ranks among the top 10 in the Indian Pharmaceutical Market (IPM).
Our gastric and hepatic care areas together have emerged as our fourth major therapy segment.
We maintain category leadership in key segments such as bulk laxatives.
We are continuing expansion through in-licensing agreements and partnerships across global markets.
From acid-related disorders to children-specific conditions and digestive irregularities, we have built a strong and diversified presence in the gastroenterology segment. Our integrated approach enables comprehensive management of gastrointestinal disorders across disease stages and age groups.
We are also strengthening our presence in the metabolic and liver health space through the introduction of advanced GLP-1 therapies. Through our agreement to co-market semaglutide injection in India under the brands Semanext® and Livarise®, we aim to expand patient access to innovative treatments for diabetes and weight management, conditions closely linked to liver health.
Our approach focuses on delivering differentiated, high-quality therapies while improving access and strengthening long-term disease management.
Our diversified gastroenterology and hepatology portfolio is aligned to key areas of clinical focus.
We offer a comprehensive acid suppression portfolio spanning trusted PPIs to next-generation P CAB therapy for disorders like GERD or peptic ulcers among others, enabling personalized treatment across disease severity.
These disorders include abdominal pain, cramps, bloating, and altered bowel habits. Our therapies target gut motility, visceral hypersensitivity, and smooth muscle spasms to improve quality of life.
Our gut-selective therapies help restore microbial balance while effectively managing infection-related symptoms and disorders such as diarrhea, gut dysbiosis, and travel-related GI infections.
This category includes problems such as chronic constipation and lifestyle-related digestive disorders. We have leading solutions designed to restore natural bowel movement while ensuring patient comfort and long-term adherence.
We have built a holistic liver care portfolio addressing disorders such as fatty liver, liver dysfunction, and metabolic liver diseases among others, through protection, regeneration, and metabolic management.
Battles poor appetite, deficiencies, and digestive concerns in children. Our targeted pediatric formulations are developed to support growth, nutrition, and digestive wellbeing.
Disclaimer: The content on this website/webpage relates to a specific therapy/therapeutic area and is intended solely for informational and educational purposes for healthcare professionals and patients across India and other global locations, is not intended to substitute professional medical advice, diagnosis, or treatment. Advice from a physician or other qualified healthcare professional must be sought for any queries regarding a medical condition or treatment. Information on this website/webpage should not be solely used or relied upon in the absence of or delay in receiving professional medical advice. While Lupin makes reasonable efforts to ensure that the information is accurate and up to date, it makes no representations or warranties regarding its completeness or accuracy and accepts no liability for reliance on such information. The information on this website/webpage is not a substitute for prescribing information or patient information leaflets accompanying any medicinal product. The information on this website/webpage is subject to change without notice and may not reflect the most current medical, scientific, or regulatory developments. All content on this website/webpage is the intellectual property of Lupin and shall not be reproduced, modified, distributed, or used for any commercial purpose without the prior written consent of Lupin.
Our comprehensive portfolio of brands addresses key aspects of gastroenterology and liver health across a range of clinical needs.
A proton pump inhibitor characterized by rapid onset and minimal potential for drug-to-drug interactions, used for gastric acid suppression.
Indications include treatment of reflux esophagitis (RE), gastric ulcer (GU), duodenal ulcer (DU), prevention of reoccurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration, prevention of reoccurrence of gastric ulcer or duodenal ulcer during NSAIDs administration, and adjunct to Helicobacter pylori (H. pylori) eradication associated with gastric ulcer, duodenal ulcer, gastric MALT lymphoma.
A pantoprazole formulation developed for gastric acid control.
A pantoprazole-based proton pump inhibitor commonly prescribed for conditions associated with acidity, heartburn, and GERD.
A PPI for management of acid related disorders.
Strengthening Comprehensive Gastro and Liver Care
Through continuous innovation, category leadership, and strategic partnerships, we have built one of the most comprehensive gastroenterology and hepatology portfolios which address everything from acidity and IBS to chronic constipation, liver health, and pediatric digestive care.
Our integrated approach ensures
We have various ongoing initiatives that cater to gastrointestinal and liver-related disorders through awareness programs, patient engagement, and global collaborations.
Gastric and liver-related disorders continue to pose a significant and growing healthcare challenge, requiring sustained innovation, early diagnosis, and accessible therapies.
At Lupin, our commitment to the gastroenterology and hepatology segment goes beyond treatment. Through advanced therapies, strategic partnerships, and large-scale awareness initiatives, we aim to improve disease management and patient outcomes globally.
